Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Daiichi Sankyo, in collaboration with Harpoon Therapeutics, is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3).’ The study aims to evaluate the safety, tolerability, and optimal dosing of HPN328 in patients with advanced cancers expressing DLL3, a protein linked to certain aggressive tumors such as small-cell lung cancer and neuroendocrine carcinoma.
Intervention/Treatment: The study is testing the biological agent Gocatamig, administered alone or in combination with Atezolizumab or Ifinatamab Deruxtecan (I-DXd). These treatments are designed to target DLL3-expressing cancers, potentially offering new therapeutic options for these challenging conditions.
Study Design: This interventional study employs a non-randomized, parallel assignment model with no masking. Its primary purpose is treatment-focused, exploring different dosing intervals and combinations to determine the most effective regimen.
Study Timeline: The study began on July 6, 2020, with the latest update submitted on September 16, 2025. These dates mark the ongoing recruitment and data collection phases, critical for advancing the study towards completion and potential regulatory review.
Market Implications: This study update could positively influence Daiichi Sankyo’s stock performance by demonstrating progress in its oncology pipeline, potentially attracting investor interest. Success in this study may also heighten competition in the cancer treatment market, particularly against other companies developing DLL3-targeted therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.